Primary Site >> Biliary tract Cancer
Gene >> IDH1
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. PMID: 22180306 |
Ref: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. PMID: 22824796 Ref: Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. PMID: 23318457 Ref: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. PMID: 23391413 Ref: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. PMID: 24185513 |
Ref: Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. PMID: 24406866 Ref: Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. PMID: 24478380 Ref: Genomic and transcriptional alterations of cholangiocarcinoma. PMID: 24532422 Ref: New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. PMID: 24563076 Ref: Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. PMID: 24569570 Ref: The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. PMID: 24880135 Ref: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. PMID: 24889489 Ref: Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. PMID: 25043045 Ref: Cholangiocarcinoma: molecular pathways and therapeutic opportunities. PMID: 25369307 Ref: IDH mutations in liver cell plasticity and biliary cancer. PMID: 25485496 Ref: Mutational landscape of intrahepatic cholangiocarcinoma. PMID: 25526346 Ref: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PMID: 25536104 |
Ref: Molecular diagnosis of intrahepatic cholangiocarcinoma. PMID: 25267595 Ref: Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. PMID: 25481493 Ref: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. PMID: 25608663 Ref: Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. PMID: 25636086 Ref: Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. PMID: 26111977 Ref: Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. PMID: 26189129 Ref: Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. PMID: 26245674 Ref: Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. PMID: 26260902 Ref: Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas. PMID: 26320466 |
Ref: Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. PMID: 26405193 Ref: Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. PMID: 26500333 Ref: Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. PMID: 26717940 Ref: Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. PMID: 26819452 Ref: Maffucci syndrome and neoplasms: a case report and review of the literature. PMID: 26920730 Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. PMID: 27102149 Ref: Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. PMID: 27231123 Ref: Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma. PMID: 27595804 Ref: IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. PMID: 27621679 Ref: Biliary cancer: Utility of next-generation sequencing for clinical management. PMID: 27622582 Ref: Molecular profiling of biliary tract cancer: a target rich disease. PMID: 27747093 Ref: Systemic therapy for biliary cancers. PMID: 27829278 Ref: Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. PMID: 28078132 |
Ref: Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss. PMID: 27864835 Ref: Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. PMID: 28124097 Ref: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. PMID: 28297679 Ref: Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. PMID: 28338651 Ref: Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. PMID: 28375741 Ref: Emerging molecular therapeutic targets for cholangiocarcinoma. PMID: 28389139 Ref: IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing. PMID: 28403884 Ref: Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. PMID: 28431889 Ref: The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. PMID: 28567120 Ref: Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. PMID: 28601826 Ref: Current biologics for treatment of biliary tract cancers. PMID: 28736630 Ref: New Horizons for Precision Medicine in Biliary Tract Cancers. PMID: 28818953 Ref: Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. PMID: 28975832 |
Ref: Targeting cholangiocarcinoma. PMID: 28844952 Ref: MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. PMID: 29113809 Ref: Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. PMID: 29274619 Ref: Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. PMID: 29278425 Ref: MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations. PMID: 29309301 Ref: Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. PMID: 29353494 Ref: Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. PMID: 29408647 Ref: PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. PMID: 29413685 Ref: Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. PMID: 29460642 Ref: Emerging molecular target antagonists for the treatment of biliary tract cancer. PMID: 29468924 Ref: Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics? PMID: 29492607 Ref: Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. PMID: 29551704 Ref: Molecular genomic landscapes of hepatobiliary cancer. PMID: 29573058 Ref: Mucinous intrahepatic cholangiocarcinoma: a distinct variant. PMID: 29698701 Ref: Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. PMID: 29733964 Ref: Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update. PMID: 29776636 Ref: Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. PMID: 29848569 Ref: Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. PMID: 29871612 Ref: New developments in systemic therapy for advanced biliary tract cancer. PMID: 29893894 Ref: Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1. PMID: 30156013 Ref: Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type. PMID: 30158952 Ref: Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. PMID: 30170977 Ref: The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. PMID: 30206411 Ref: Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. PMID: 30218788 Ref: IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. PMID: 30278918 Ref: A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation. PMID: 30352944 |